Phase 1 Cancer trials recruiting now

All Cancer trials, every phase

Other phases for Cancer

Phase 1 Cancer trials

• A Dose Finding Phase 1 of Sarilumab Plus Capecitabine in HER2/Neu-Negative Metastatic Breast Cancer and a Single-arm, Historically-controlled Phase 2 Study of Sarilumab Plus Capecitabine in Stage I-III Triple Negative Breast Cancer With High-Risk Residual Disease (EMPOWER)
  NCT04333706 · Phase: Phase 1, Phase 2 · Ages: 18 Years to 99 Years · Sex: All (male and female) · 3 locations
• A Phase 1 Study of CPO301 in Adult Patients With Advanced or Metastatic Solid Tumors
  NCT05948865 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 14 locations
• A Phase 1 Study of IM-1617 in Participants With Advanced Cancer
  NCT07578571 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 6 locations
• A Phase 1 Study of JMT108 in Participants With Advanced Solid Tumors
  NCT07317505 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 6 locations
• A Study Assessing KB707 for the Treatment of Locally Advanced or Metastatic Solid Tumors
  NCT05970497 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 15 locations
• A Study of OR502, a Monoclonal Antibody Targeting LILRB2, Alone and in Combination With Anticancer Agents
  NCT06090266 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 4 locations
• A Study to Evaluate Safety, Tolerability and Preliminary Activity of AGX101 in Participants With Advanced Solid Tumors
  NCT06440005 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 12 locations
• A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumors That Express EGFR and Have Lost HLA-A*02 Expression
  NCT06682793 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 30 locations
• A Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression
  NCT06051695 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 12 locations
• A Study to Learn About Study Medicine ALTA3263 in Adults With Advanced Solid Tumors With KRAS Mutations
  NCT06835569 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 12 locations
• ACTengine® IMA203/IMA203CD8 as Monotherapy or in Combination With Nivolumab in Recurrent and/or Refractory Solid Tumors
  NCT03686124 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 21 locations
• Biomarker-Guided Allogeneic Single-Target or Dual-Target CAR-NK Cell Therapy for Advanced Solid Tumors
  NCT07410494 · Phase: Phase 1, Phase 2 · Ages: 8 Years to 85 Years · Sex: All (male and female) · 3 locations
• EBNK-001 Allogeneic NK Cells With Low-Dose IL-15 ± Pembrolizumab in Advanced Solid Tumors
  NCT07410676 · Phase: Phase 1, Phase 2 · Ages: No age limits stated · Sex: All (male and female) · 1 location
• FOG-001 in Locally Advanced or Metastatic Solid Tumors
  NCT05919264 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 33 locations
• GPC3/Mesothelin/Claudin18.2/GUCY2C/B7-H3/PSCA/PSMA/MUC1/TGFβ/HER2/Lewis-Y/AXL/EGFR-CAR-T Cells Against Cancers
  NCT03198052 · Phase: Phase 1 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 2 locations
• Phase 1 Trial of SYNC-T - Immunotherapy for Patients With Advanced/Metastatic Solid Tumors
  NCT05544240 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 2 locations
• Phase 1a and Phase 2 Study for Safety, Preliminary Efficacy, PK and PD of ST-067
  NCT04787042 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 12 locations
• Phase I Study of SYS6043 in Patients With Advanced/Metastatic Solid Tumors
  NCT07424547 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 15 locations
• Phase I/II Clinical Study to Evaluate VB15010 Tablets in Patients With Advanced Solid Tumors
  NCT06819215 · Phase: Phase 1, Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 2 locations
• Positron Emission Tomography (PET) Imaging of Thrombosis
  NCT03830320 · Phase: Phase 1 · Ages: 18 Years to 85 Years · Sex: All (male and female) · 1 location
• Precision Therapy for Solid Tumors: Synergistic CDK4/6 Inhibition and Anti-VEGF Targeting LncRNA
  NCT06307249 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 4 locations
• TTX-080 HLA-G Antagonist in Subjects With Advanced Cancers
  NCT04485013 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 41 locations

Common questions

What does Phase 1 mean?

See how clinical trials work.

Is this list complete?

No. For the full record, search ClinicalTrials.gov.